Advertisement
Product › Details
Idelvion®
Next higher product group | factor IX, recombinant | |
Organisation | CSL Ltd. (ASX: CSL, USOTC:CSLLY) | |
Group | CSL (Group) | |
Thermo Fisher Scientific Inc.. (9/23/21). "Press Release: Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland". Bremen.
State-of-the-art facility provides pathway from development to large-scale biologics production
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with CSL Limited announced last year. The Lengnau site will become part of Thermo Fisher's global biologics manufacturing network, and approximately 200 employees will join Thermo Fisher.
The Lengnau site is a 1.5 million square-foot facility that will leverage highly flexible bioproduction technologies, including both single-use and stainless steel with up to 12,500L bioreactor capacity. This will provide biopharma companies with a pathway from development to large-scale production as manufacturing needs evolve.
"We are excited to add the new Lengnau site to our global biologics manufacturing network and we are thrilled to welcome more than 200 new colleagues to Thermo Fisher," said Michel Lagarde, executive vice president of Thermo Fisher Scientific. "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow."
Following completion of site construction in 2022, Thermo Fisher will initially support manufacturing of CSL's next-generation recombinant factor IX product Idelvion® for patients with hemophilia B. Over time, Thermo Fisher plans to expand the use of the site to include additional biopharma customers.
The Lengnau site is an important expansion of Thermo Fisher's biologics manufacturing network that includes Princeton, NJ and St. Louis, MO, USA; Groningen, NL; Brisbane, AU; and Hangzhou, China.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Raf Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Record changed: 2023-07-10 |
Advertisement
More documents for pharmaceutical
- [1] Memo Therapeutics AG. (5/7/24). "Press Release: Memo Therapeutics Increases Series C Financing to CHF 45 Million". Schlieren....
- [2] PeptiDream Inc.. (4/30/24). "Press Release: PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis". Kanagawa....
- [3] Miltenyi Biotec B.V. & Co. KG. (4/29/24). "Press Release: Miltenyi Biotec and MiLaboratories Announce Strategic Partnership to Advance Next-generation Therapies". Bergisch Gladbach & San Francisco, CA....
- [4] Theolytics Ltd.. (4/17/24). "Press Release: Theolytics Successfully Closes Latest Financing Raising Total of £19M ($24.5M) and Welcomes Sound Bioventures as New Investor". Oxford....
- [5] KBI Biopharma, Inc.. (4/15/24). "Press Release: KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer". Durham, NC....
- [6] Naobios. (4/15/24). "Press Release: Naobios and Sumagen Sign Exclusive Partnership to Develop HIV Vaccine". Nantes....
- [7] Nanoform Finland Oyj. (4/11/24). "Press Release: Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan". Helsinki....
- [8] Asahi Kasei Bioprocess. (4/11/24). "Press Release: Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development". Düsseldorf, Tokyo & New York, NY....
- [9] TORL BioTherapeutics, LLC. (4/10/24). "Press Release: TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline". Los Angeles, CA....
- [10] Boehringer Ingelheim. (4/9/24). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets". Ingelheim & Shanghai....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top